MENU
ARVN
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Arvinas (ARVN) Ownership - Who owns Arvinas?
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins... Show more
Industry: #Biotechnology
Profile
Industry
Biotechnology
Address
395 Winchester Avenue
Phone
+1 203 535-1456
Employees
445
Web
https://www.arvinas.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
493.78M
P/E Ratio
N/A
Total Cash
1.04B
Projected Growth
N/A
Total Debt
9.7M
Revenue
263.4M
Risk (Beta)
1.90
Dividend Yield
N/A
Total Cash/Share
15.11
Total Debt/Equity
N/A
Revenue/Share
3.66 USD as % of share price
Fundamentals
ARVN
Capitalization
494M
P/E Ratio
N/A
Risk (Beta)
1.90
Dividend Yield
N/A
Total Cash
1.04B
Total Cash/Share
15.11
Total Debt
9.7M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
3.66%
Revenue
263M
ROE
N/A
Book Value
562M
P/B Ratio
0.88
Cash Flow
N/A
Earnings
-2.77
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
100K
Current Ratio
4.64
Current Revenue Per Employee
137674.42
Dividends Per Share - Security
N/A
EBITDA
-243.6M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-16.60
Shares Held By Institutions
3.39B
Shares Outstanding - Current
68.8M
Total Liabilities
530M
Total Volume MTD
N/A
Value
1
Gain YTD
-62.546
View a ticker or compare two or three
VS
VS
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a developer of therapies to degrade disease-causing proteins
Industry Biotechnology
Profile
Fundamentals
Details
Industry
Biotechnology
Address
395 Winchester Avenue
Phone
+1 203 535-1456
Employees
445
Web
https://www.arvinas.com